Partners in Financial Planning Takes Position in Pfizer Inc. (NYSE:PFE)

Partners in Financial Planning bought a new position in Pfizer Inc. (NYSE:PFE) during the fourth quarter, HoldingsChannel reports. The fund bought 8,835 shares of the biopharmaceutical company’s stock, valued at approximately $234,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer in the fourth quarter worth about $26,000. Rialto Wealth Management LLC purchased a new stake in Pfizer in the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer during the 4th quarter worth approximately $28,000. Noble Wealth Management PBC purchased a new position in Pfizer during the fourth quarter valued at approximately $31,000. Finally, Curio Wealth LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $32,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PFE has been the topic of several recent analyst reports. Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Bank of America reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $25.20 on Monday. The firm has a fifty day simple moving average of $26.06 and a two-hundred day simple moving average of $26.90. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $142.93 billion, a P/E ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.10 earnings per share. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.